Skip to main content
Premium Trial:

Request an Annual Quote

SCT, AB Biosciences Collaborate on Antibodies Using NGS

NEW YORK (GenomeWeb News) – Single Cell Technology and AB Biosciences today announced a collaboration aimed at identifying therapeutic antibodies.

SCT will use its technology called Antibody Biologix to massively screen plasma cells and measure the kinetics of secreted antibodies. It also will use next-generation sequencing to sequence the cognate light and heavy chain mRNA.

ABB will select antibody targets, engineer protein antigens, and develop tools for characterizing antibodies identified by SCT.

Financial and other terms of the collaboration were not disclosed.

Based in San Jose, Calif., SCT identifies and optimizes antibodies. On its website, it said that its platform analyzes antibodies and mRNA from individual antibody secreting cells. Antibodies are evaluated for their affinity and specificity, while mRNA encoding the cognate light and heavy chains is analyzed by NGS.

Allston, Mass.-based AB Biosciences engineers and produces niche protein molecules.